Provided by Tiger Trade Technology Pte. Ltd.

Zevra Therapeutics

11.65
-0.2200-1.85%
Post-market: 11.870.2200+1.89%17:21 EDT
Volume:784.40K
Turnover:9.20M
Market Cap:688.69M
PE:12.13
High:12.01
Open:11.98
Low:11.45
Close:11.87
52wk High:15.04
52wk Low:7.16
Shares:59.11M
Float Shares:53.86M
Volume Ratio:0.89
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9602
EPS(LYR):1.35
ROE:34.80%
ROA:8.74%
PB:3.16
PE(LYR):8.63

Loading ...

Zevra Therapeutics Inc : Canaccord Genuity Raises Target Price to $29 From $24

THOMSON REUTERS
·
Jun 09

Zevra Therapeutics Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jun 08

Zevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald

TIPRANKS
·
Jun 08

Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for Miplyffa

THOMSON REUTERS
·
Jun 08

Zevra Therapeutics grants 33,000 stock options to four new employees under inducement plan

Reuters
·
May 30

Zevra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 30

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 30

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
May 27

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

GlobeNewswire
·
May 12

Zevra Therapeutics Earnings Call Highlights Growth Pivot

TIPRANKS
·
May 11

Analysts Are Bullish on These Healthcare Stocks: Zevra Therapeutics (ZVRA), CG Oncology, Inc. (CGON)

TIPRANKS
·
May 09

Zevra Therapeutics (ZVRA) Is Up 8.2% After Debt-Free Turnaround And Rare Disease Refocus – What’s Changed

Simply Wall St.
·
May 09

Zevra Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
May 08

Analysts Are Bullish on Top Healthcare Stocks: Zevra Therapeutics (ZVRA), Medicus Pharma Ltd (MDCX)

TIPRANKS
·
May 08

Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM

TIPRANKS
·
May 08

Zevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Execution, Debt-Free Balance Sheet Support Upside with Price Target Maintained at $26

TIPRANKS
·
May 07

Zevra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Rare disease drugmaker Zevra Therapeutics Q1 revenue jumps 78%

Reuters
·
May 07

Zevra Q1 FY26 net income swings to $37.9 million; revenue rises 78% to $36.2 million

Reuters
·
May 07

Zevra Therapeutics Q1 EPS $0.60 Beats $0.07 Estimate, Sales $36.220M Beat $31.960M Estimate

Benzinga Earnings
·
May 07